Thomas Pålsson
Director of Finance/CFO bei CIRCHEM AB
Profil
Thomas Pålsson is currently the Chief Financial Officer at Toleranzia AB, Monivent AB, Stayble Therapeutics AB, CirChem AB, and is also the Owner & Procurator at Besattningen 1 Kommanditbolag.
He previously held the position of Chief Financial Officer at Arexis AB and Integrum AB.
Mr. Pålsson received a graduate degree and an MBA from Handelshögskolan i Göteborg.
Aktive Positionen von Thomas Pålsson
| Unternehmen | Position | Beginn |
|---|---|---|
| CIRCHEM AB | Director of Finance/CFO | 01.09.2020 |
| STAYBLE THERAPEUTICS AB | Director of Finance/CFO | 01.01.2018 |
| MONIVENT AB | Director of Finance/CFO | - |
| TOLERANZIA AB | Director of Finance/CFO | 30.10.2023 |
| Fullriggaren Konsult AB | Director of Finance/CFO | - |
| Besattningen 1 Kommanditbolag | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Thomas Pålsson
| Unternehmen | Position | Ende |
|---|---|---|
| INTEGRUM AB | Director of Finance/CFO | 09.10.2019 |
Arexis AB
 Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden. | Director of Finance/CFO | - |
Ausbildung von Thomas Pålsson
| Handelshögskolan i Göteborg | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| TOLERANZIA AB | Health Technology |
| MONIVENT AB | Health Technology |
| INTEGRUM AB | Health Technology |
| STAYBLE THERAPEUTICS AB | Health Technology |
| CIRCHEM AB | Process Industries |
| Private Unternehmen | 3 |
|---|---|
Arexis AB
Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden. | Health Technology |
| Fullriggaren Konsult AB | |
| Besattningen 1 Kommanditbolag |
